Novacyt

Novacyt Financial Debt Ratio

The Financial Debt Ratio of Novacyt (ALNOV.PA) as of Oct 18, 2026 is 25.92 %. In the previous year, Financial Debt Ratio was 16.82 % — a change of 54.13% (higher).

Financial Debt Ratio

25.92 %

YoY

54.13%

Last updated:

Financial Debt Ratio of Novacyt is 2025 25.92 % . Financial Debt Ratio of Novacyt was 2024 16.82 % . It decreases by 54.13% higher compared to the previous year.

The Novacyt Financial Debt Ratio history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financial Debt Ratio
Date
Financial Debt Ratio
Jan 1, 2018
17.86 GBP
Jan 1, 2019
38.02 GBP
Jan 1, 2020
1.18 GBP
Jan 1, 2021
1.02 GBP
Jan 1, 2022
0.62 GBP
Jan 1, 2023
10.24 GBP
Jan 1, 2024
16.82 GBP
Jan 1, 2025
25.92 GBP
The Novacyt Financial Debt Ratio history
YEARFinancial Debt RatioYoY
25.92 %+54.13%
16.82 %+64.21%
10.24 %+1,554.78%
0.62 %-39.21%
1.02 %-14.00%
1.18 %-96.89%
38.02 %+112.93%
17.86 %+56.05%
11.44 %-44.55%
20.64 %-22.67%
26.69 %+439.75%
4.94 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Novacyt Stock analysis

What does Novacyt do? Novacyt SA is a leading biotechnology company specializing in the development and marketing of diagnostic products and technologies. The company was founded in 2006 and has experienced impressive growth since then. Its headquarters are located in Paris. Novacyt's business model revolves around the development and marketing of diagnostic products and technologies, particularly molecular diagnostic kits and reagents used for identification and quantification of microorganisms, viruses, and genetic differences. These products are commonly used in medical research, clinical diagnostics, and environmental analysis. Novacyt is divided into several divisions, each offering different products and services. Its diagnostic business specializes in the research, development, and marketing of molecular diagnostic kits, including the Primerdesign Kits specifically designed for COVID-19 identification. The company also provides laboratory and service offerings, such as DNA sequencing, qPCR analysis, sample preparation, and PCR disinfection. Additionally, Novacyt offers various diagnostic tests capable of detecting genetic differences and mutations. Its PathFlow division focuses on improving the process from diagnosis to therapy and follow-up, particularly for oncology patients. In response to the COVID-19 pandemic, Novacyt quickly launched a PCR test kit for COVID-19, which has been approved in numerous countries worldwide. Novacyt has successfully established itself as a key player in the fight against the pandemic. In summary, Novacyt SA is a leading biotechnology company specializing in the development and marketing of diagnostic products and technologies. Through its divisions, the company ensures the optimal utilization of molecular diagnostic tests. Novacyt has become an important player in the fight against the pandemic through its rapid response and development of molecular diagnostic kits for COVID-19, establishing itself as a reliable and innovative partner for medical research and clinical diagnostics. Novacyt is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Novacyt stock

Financial Debt Ratio of Novacyt is 25.92 % in 2025.

Financial Debt Ratio of Novacyt changed from 16.82 % to 25.92 %, representing a 54.13% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Financial Debt Ratio Novacyt since 2006 – with annual values, charts, and detailed analysis.

The financial debt ratio measures interest-bearing financial debt as a percentage of total assets. It isolates funded debt from trade and other non-financial obligations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Debt Ratio's Novacyt with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Novacyt

All Key Metrics — Novacyt